[The antiviral activity of deitiforin in experimental para-influenza infection].
Deitiforin in HEp-2 cell culture was shown to inhibit replication of the reference PIV-3 strain when administered 1 hour before virus inoculation. The most marked effect of the drug was observed in the first 4 days of observation. In experimental newborn mice infected with parainfluenza virus 3 deitiforin protected the animals from developing the infection. In humans given deitiforin reaction to vaccination was found to develop 5-6 times more rarely than in the control group, PIV-3 could be isolated twice as rarely, and a diagnostically significant rise of specific antibody levels was observed less frequently.
Boldasov
V K
VK
Kalinina
N A
NA
Revunova
O V
OV
Guseva
V M
VM
Leonov
V M
VM
Sukhinin
V P
VP
Il'enko
V I
VI
D000328:Adult; D000818:Animals; D000833:Animals, Suckling; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D002460:Cell Line; D002478:Cells, Cultured / Q000187:drug effects / Q000382:microbiology; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D051379:Mice; D009930:Organic Chemicals; D010224:Parainfluenza Virus 3, Human / Q000276:immunology; D018184:Paramyxoviridae Infections / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D000998:Antiviral Agents; D009930:Organic Chemicals; D014765:Viral Vaccines; C060204:deitiforin
Protivovirusnaia aktivnost' deĭtiforina pri éksperimental'noĭ paragrippoznoĭ infektsii.